Aetiology, clinical features, diagnostic studies, and outcomes of community-acquired pneumonia in kidney transplant recipients admitted to hospital: a multicentre retrospective French cohort study.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 05 07 2022
revised: 06 12 2022
accepted: 18 12 2022
medline: 4 4 2023
pubmed: 28 12 2022
entrez: 27 12 2022
Statut: ppublish

Résumé

To assess the aetiology, clinical features, diagnostic studies and outcomes of community-acquired pneumonia (CAP) in a French cohort of hospitalized kidney transplant recipients. We performed a retrospective, multicentre study in kidney transplant recipients admitted to ten French centres for CAP from January 2016 to December 2018. CAP discharge diagnoses were clinically and radiologically validated. We assessed a descriptive analysis of all confirmed CAP including medical ward and intensive care unit admissions. One hundred sixty-five CAP episodes in 132 patients were included. Median time from transplantation to admission was 6.4 (interquartile range, 1.6-12.3) years, with corticosteroid exposure in 112/165 (67.9%) cases. Sputum culture was performed in 47/165 (28.5%) cases including 7/47 (14.9%) positive samples. Bronchoscopy was performed in 87/165 (52.7%) cases with pathogens identified in 39/87 (44.8%) cases. Microbiological studies led to identifying a respiratory pathogen in 64/165 (38.8%) CAP episodes including 11/64 (17.2%) polymicrobial cases. Among these 64 episodes, 75 microorganisms were identified; 46/75 (61.3%) were core respiratory pathogens and 29/75 (38.7%) were opportunistic or drug-resistant organisms including Pneumocystis jirovecii 9/75 (12%), Pseudomonas aeruginosa 5/75 (6.7%), multidrug-resistant Enterobacteriaceae 4/75 (5.3%), and Aspergillus 4/75 (5.3%). Patients required intensive care unit admission in 26/165 (15.8%) episodes, invasive ventilation in 20/165 (12.1%) cases, and 22/165 (13.3%) needed in-hospital dialysis. CAP episodes occurred in kidney transplant recipients with a long history of immunosuppressive drug exposure. Diagnostic studies identified a microorganism in more than one-third of CAP episodes, including drug-resistant and opportunistic pathogens.

Identifiants

pubmed: 36574948
pii: S1198-743X(22)00638-3
doi: 10.1016/j.cmi.2022.12.014
pii:
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

542.e1-542.e5

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Benoît Schwartz (B)

Department of Nephrology, Reims University Hospitals, Reims, France.

Vincent Dupont (V)

Department of Nephrology, Reims University Hospitals, Reims, France; French Clinical Research Infrastructure Network, Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT), Reims, France; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Sandra Dury (S)

Department of Respiratory Diseases, Reims University Hospitals, Reims, France; EA7509 IRMAIC, University of Reims Champagne-Ardenne, Reims, France.

Aline Carsin-Vu (A)

Department of Radiology, Reims University Hospitals, Reims, France.
Université de Reims Champagne-Ardenne, INSERM, CHU de Reims, Laboratoire de Bactériologie-Virologie-Hygiène Hospitalière-Parasitologie-Mycologie, P3Cell, Reims, France; Laboratoire de Bactériologie-Virologie-Hygiène Hospitalière-Parasitologie-Mycologie, Reims University Hospitals, Hôpital Robert Debré, Reims, France.

Sophie Caillard (S)

Department of Nephrology and Transplantation, Strasbourg University Hospitals, Strasbourg, France; INSERM 1109, Fédération de Médecine Translationnelle, LabEx TRANSPLANTEX, Strasbourg, France.

Luc Frimat (L)

Department of Nephrology and Transplantation, Nancy University Hospitals, Vandoeuvre les Nancy, France; EA 4360, INSERM CIC-EC CIE6, Apemac, Vandoeuvre les N, France.

Stephane Sanchez (S)

Clinical Research and Methological Unit, Troyes Hospital, Troyes, France.

Betoul Schvartz (B)

Department of Nephrology, Reims University Hospitals, Reims, France.

Firouzé Bani-Sadr (F)

Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, Reims University Hospitals, Reims, France.
Department of Research and Public Health, Reims University Hospitals, Reims, France.
Department of Nephrology, Reims University Hospitals, Reims, France.
Intensive Care Department, Reims University Hospitals, Reims, France. Electronic address: agoury@chu-reims.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH